{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:34:24Z","timestamp":1790688864142,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Isoniazid preventive therapy (IPT) is recommended for tuberculosis prevention yet data on the safety of first-trimester pregnancy exposure are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Planned secondary analysis in a TB prevention trial of adverse pregnancy outcomes among participants assigned to 9-month IPT who became pregnant during (IPT-exposed) or after (unexposed) IPT. Regression models compared binary outcomes of a composite adverse outcome (any non-live birth, excluding induced abortion); preterm delivery &amp;lt;37 weeks; and low birth weight &amp;lt;2500\u2005g) among exposure groups. Models were adjusted for latent TB infection, maternal age, CD4 count, and antiretroviral therapy (ART).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 128 participants had a known pregnancy outcome; 39 IPT-exposed and 89 unexposed. At pregnancy outcome, ART use was lower in IPT-exposed (79%) than unexposed women (98%). Overall, 29 pregnancies ended in a composite adverse outcome (25 spontaneous abortions, 2 stillbirths and 2 ectopic pregnancies), 15 preterm deliveries, and 10 infants with low birth weight. IPT was associated with the composite adverse outcome adjusting for covariates at enrollment (adjusted relative risk [aRR] 1.98; 95% confidence interval [CI] 1.15, 3.41), but the effect was attenuated when adjusted for covariates at pregnancy outcome (aRR 1.47; 95% CI .84, 2.55); IPT was not associated with preterm delivery (relative risk [RR] 0.87; 95% CI .32\u20132.42) or low birth weight (RR 1.01; 95% CI .29, 3.56).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>First-trimester IPT exposure was associated with nearly two-fold increased risk of fetal demise, mostly spontaneous abortion, though the association was attenuated when adjusted for covariates proximal to pregnancy outcome including ART use. Further study is needed to inform TB prevention guidelines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad583","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:56:05Z","timestamp":1695920165000},"page":"667-673","source":"Crossref","is-referenced-by-count":12,"title":["Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First Trimester"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-2718","authenticated-orcid":false,"given":"Amita","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Hughes","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Leon","family":"Cruz","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre and Center of Excellence in Tuberculosis, Faculty of Medicine Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noluthando","family":"Mwelase","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Witwatersrand , Johannesburg , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Severe","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Les Centres GHESKIO , Port-au-Prince , Haiti"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayotunde","family":"Omoz-Oarhe","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Clinical Trials Unit , Gaborone , Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaerolwe","family":"Masheto","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Clinical Trials Unit , Gaborone , Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moran","sequence":"additional","affiliation":[{"name":"Public Health and Scientific Research Unit, Social & Scientific Systems, a DLH Company , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance A","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of California San Diego School of Medicine , La Jolla, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-6037","authenticated-orcid":false,"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2024032020261748000_ciad583-B1","author":"Organization WH","year":"2011"},{"key":"2024032020261748000_ciad583-B2","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018"},{"key":"2024032020261748000_ciad583-B3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/1471-0528.14408","article-title":"Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis","volume":"124","author":"Sobhy","year":"2017","journal-title":"BJOG"},{"key":"2024032020261748000_ciad583-B4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/cid\/civ991","article-title":"Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: consensus statements from an international expert panel","volume":"62","author":"Gupta","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024032020261748000_ciad583-B5","doi-asserted-by":"crossref","first-page":"1901967","DOI":"10.1183\/13993003.01967-2019","article-title":"The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis","volume":"55","author":"Hamada","year":"2020","journal-title":"Eur Respir J"},{"key":"2024032020261748000_ciad583-B6","doi-asserted-by":"crossref","first-page":"871321","DOI":"10.3389\/fsurg.2022.871321","article-title":"Safety evaluation of antituberculosis drugs during pregnancy: a systematic review and meta-analysis","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Surg"},{"key":"2024032020261748000_ciad583-B7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/518974","article-title":"Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in pune, India, 2002\u20132005","volume":"45","author":"Gupta","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024032020261748000_ciad583-B8","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0016-2016","article-title":"Tuberculosis and pregnancy-maternal, fetal, and neonatal considerations","volume":"4","author":"Gould","year":"2016","journal-title":"Microbiol Spectr"},{"key":"2024032020261748000_ciad583-B9","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/cid\/cis732","article-title":"Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps","volume":"55","author":"Mathad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024032020261748000_ciad583-B10","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1016\/S2214-109X(14)70330-4","article-title":"Tuberculosis in pregnancy: an estimate of the global burden of disease","volume":"2","author":"Sugarman","year":"2014","journal-title":"Lancet Glob Health"},{"key":"2024032020261748000_ciad583-B11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1813060","article-title":"Isoniazid preventive therapy in HIV-infected pregnant and postpartum women","volume":"381","author":"Gupta","year":"2019","journal-title":"N Engl J Med"},{"key":"2024032020261748000_ciad583-B12","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1093\/cid\/ciaa1482","article-title":"Individual and composite adverse pregnancy outcomes in a randomized trial on isoniazid preventative therapy among women living with human immunodeficiency virus","volume":"72","author":"Theron","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024032020261748000_ciad583-B13","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.eclinm.2023.101912","article-title":"Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial","volume":"58","author":"Cherkos","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024032020261748000_ciad583-B14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2024032020261748000_ciad583-B15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2024032020261748000_ciad583-B16"},{"key":"2024032020261748000_ciad583-B17","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1093\/cid\/ciz1224","article-title":"Safety and effectiveness of isoniazid preventive therapy in pregnant women living with human immunodeficiency virus on antiretroviral therapy: an observational study using linked population data","volume":"71","author":"Kalk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024032020261748000_ciad583-B18","doi-asserted-by":"crossref","first-page":"195637","DOI":"10.1155\/2013\/195637","article-title":"Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy","volume":"2013","author":"Taylor","year":"2013","journal-title":"Infect Dis Obstet Gynecol"},{"key":"2024032020261748000_ciad583-B19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","article-title":"Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials","volume":"15","author":"Moro","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2024032020261748000_ciad583-B20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/cid\/ciz1024","article-title":"Isoniazid preventive therapy and pregnancy outcomes in women living with human immunodeficiency virus in the Tshepiso cohort","volume":"71","author":"Salazar-Austin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024032020261748000_ciad583-B21","doi-asserted-by":"crossref","first-page":"e1002882","DOI":"10.1371\/journal.pmed.1002882","article-title":"Inclusion of key populations in clinical trials of new antituberculosis treatments: current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons","volume":"16","author":"Gupta","year":"2019","journal-title":"PLoS Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad583\/52603686\/ciad583.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/3\/667\/57037673\/ciad583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/3\/667\/57037673\/ciad583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T20:26:46Z","timestamp":1710966406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/3\/667\/7285267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2024,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad583","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,15]]},"published":{"date-parts":[[2023,9,28]]}}}